Impel NeuroPharma Announces First Patient Dosed in Phase 1 Clinical Trial of INP104
Impel NeuroPharma announced that the first patient was dosed in the recently-initiated Phase 1 clinical trial of INP104 for acute migraine headache. INP104 is a novel dihydroergotamine…
Read More...
Read More...
